CAS 1206681-39-1
:Namilumab
Description:
Namilumab is a monoclonal antibody that targets the protein known as granulocyte-macrophage colony-stimulating factor (GM-CSF), which plays a crucial role in the immune response and inflammation. By inhibiting GM-CSF, Namilumab aims to reduce inflammation and modulate immune responses, making it a potential therapeutic agent for autoimmune diseases such as rheumatoid arthritis and other inflammatory conditions. The substance is characterized by its specificity for GM-CSF, which helps in minimizing off-target effects commonly associated with broader immunosuppressive therapies. Namilumab is typically administered via injection, and its pharmacokinetics involve a prolonged half-life, allowing for less frequent dosing. Clinical trials have been conducted to evaluate its efficacy and safety profile, focusing on its ability to improve symptoms and quality of life in patients with chronic inflammatory diseases. As with any therapeutic monoclonal antibody, potential side effects may include infusion reactions and increased susceptibility to infections due to its immunomodulatory effects.
Formula:Unspecified
Synonyms:- IZN 101
- Immunoglobulin G1, anti-(human colony-stimulating factor 2) (human monoclonal MT203 heavy chain), disulfide with human monoclonal MT203 κ-chain, dimer
- Namilumab
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 2 products.
Namilumab
CAS:Namilumab (AMG203) is a humanised IgG1 monoclonal antibody that neutralises GM-CSF. rheumatoid arthritis and active axial spondyloarthritis.Purity:95%Color and Shape:Liquid
